A first-in-class antisense oligonucleotide ... Olezarsen is an mRNA-targeted ligand conjugated antisense medicine that works by lowering the body's production of apolipoprotein C-III, a key ...

Added to this is Ionis' Ligand Conjugated Antisense ("LICA") technology ... Both QALSODY and SPINRAZA are administered via lumbar puncture, allowing them to target the central nervous system ...

Ionis' innovative antisense ... relative to non-conjugated antisense medicines. This approach has enabled Ionis to secure five commercial approvals for drug candidates - SPINRAZA (nusinersen ...

Recent years have witnessed a wave of FDA approvals and regulatory greenlights for novel antisense oligonucleotide therapies, significantly boosting confidence in their clinical potential. For ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... field include Biogen’s ASO Spinraza (nusinersen) approved ...

Spinraza is delivered via intrathecal injection, also known as lumbar puncture. The route of delivery gets the antisense oligonucleotide into the cerebrospinal fluid and thereby provides direct ...

will be available in January 2024 now that the U.S. FDA has approved Ionis Pharmaceuticals Inc.’s Wainua (eplontersen), a ligand-conjugated antisense oligonucleotide.

Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence ... mediated endocytosis for uptake of oligonucleotide therapeutics to specific ...

In a study published earlier this year in Molecular Therapy, Japanese researchers have found that antisense ... delivery of lipid-ligand conjugated DNA/RNA heteroduplex oligonucleotide to ischemic ...

today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics. The collaboration will leverage Orbit’s ...